secwatch.observer — SEC 8-K summary
======================================

Issuer:     Iterum Therapeutics plc (ITRMF)
CIK:        0001659323
Form:       8-K
Filed at:   2024-05-31T23:59:59+00:00
Accession:  0000950170-24-066932
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Iterum receives FDA acceptance of oral sulopenem NDA resubmission; PDUFA date Oct 25, 2024
--------------------------------------------------------------------------------

- FDA accepted resubmission of NDA for oral sulopenem for uUTIs in adult women; PDUFA action date set for October 25, 2024.
- Nasdaq granted 180-day extension until September 30, 2024 to regain compliance with minimum stockholders' equity requirement.
- CMO Sailaja Puttagunta steps down effective May 31, 2024; will serve as consultant at $400/hour during regulatory review.
- Resubmission includes REASSURE trial data showing oral sulopenem non-inferior to Augmentin and statistically superior for overall success.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659323/000095017024066932/0000950170-24-066932-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659323/000095017024066932/itrm-20240529.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-066932

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer